Thursday, Oct 5, 1995

Genentech's Blood Platelet Factor (TPO) Enters the Clinic as Phase I Trial Begins

Company continues its full effort to develop blood platelet factor

South San Francisco, Calif. -- October 5, 1995 --

Genentech, Inc. (NYSE: GNE) announced today that it has begun Phase I clinical trials of thrombopoietin (TPO) for thrombocytopenia (reduction in platelets) in cancer patients treated with chemotherapy.

The start of the trial follows an extensive research effort to characterize the preclinical safety and efficacy of TPO before entering the clinic.

Genentech, Inc. is a leading biotechnology company that discovers, develops, manufactures and markets human pharmaceuticals for significant unmet medical needs. The company has headquarters in South San Francisco, California and is traded on the New York and Pacific Stock Exchanges under the symbol GNE.

# # #